The lungs are the first line of environmental exposure. Two billion people are exposed to indoor smoke, one billion people inhale outdoor polluted air, and one billion people are exposed to tobacco smoke... Respiratory diseases cause a huge health burden all over the world. Five of the respiratory diseases, including chronic obstructive pulmonary disease, asthma, acute lower respiratory infection, tuberculosis and lung cancer, are the most common causes of serious diseases and deaths in the world. Every National Public Health Department needs to raise awareness, focus on prevention and control methods, and provide treatments for these diseases.

In 2020, the COVID-19 epidemic is raging around the world ubiquitously and pervasively. Its spread and the resulting impact have led to an unprecedented global crisis. In response to this war without smoke of gunpowder, YHLO has developed a series of weapons for COVID-19 diagnosis, including SARS-CoV-2 antigen, IgG, IgM, IgA, and neutralizing antibodies detection on various platforms. Antibody detection can identify people who have been immunized, and will also provide an evidence for subsequent refined isolation and removal of prevention and control measures. With the development of effective vaccines and treatment suggestions, YHLO hopes to work with the international community and follow scientific-based guidelines to successfully prevent the spread of the COVID-19.

Under the COVID-19 epidemic, the differential diagnosis is a vital step in dealing with respiratory diseases. Different pathogens have differences in infectiousness, disease severity, medication, and disease course management. A definite diagnosis can be applied for precise treatment and management. Clinically, it is difficult to distinguish pneumonia caused by Mycoplasma or Chlamydia pneumoniae from other atypical microorganisms. Therefore, YHLO provides Mycoplasma/Chlamydia pneumoniae antibody detection kits on the chemiluminescence (CLIA) platform to facilitate the differential diagnosis from COVID-19 or other infections. Meanwhile, YHLO also provides PCT as a biomarker to distinguish bacterial infection from non-bacterial infections or inflammations.

Lung cancer is a malignant tumor with the highest incidence and fatality rate in the world. According to the appearance under the microscope, lung cancer can be divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is more common and currently accounts for about 87% of lung cancer cases. The symptoms of SCLC and NSCLC may be similar and may include: persistent cough, chest pain, shortness of breath, wheezing, loss of appetite, weight loss, and abnormal fatigue. Some patients may also experience swelling of the face and neck. Cytokeratin 19 fragment (CYFRA21-1) is a soluble protein in the blood, which has relatively high sensitivity and specificity as a tumor marker for non-small cell lung cancer. Neuron specific enolase (NSE) can play a certain auxiliary role in the diagnosis and treatment of SCLC. YHLO provides CYFRA21-1 and NSE detection kits on the CLIA platform for early diagnosis and differentiation of the pathological type of lung cancer.